ArticleAmerican journal of translational research2025
Study of NOX4/ROS/NF-κB signaling pathway in anti-ischemia-reperfusion injury effect and mechanism of STQJD.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the effects of Shu-Tiao Qi-Ji Decoction (STQJD) on a rat model of cerebral ischemia-reperfusion injury and to elucidate its mechanism of action.
methodsThe therapeutic effects of STQJD on ischemic stroke (IS) were assessed using neurobehavioral scores, 2,3,5-Triphenyltetrazolium chloride (TTC), Nissl and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. Network pharmacology was used to investigate the potential mechanisms of STQJD. Reactive Oxygen Species (ROS) content and expression levels of inflammatory markers in rat serum were detected. The mRNA and protein expression levels of Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), NADPH oxidase 4 (NOX4), Tumor necrosis factor-alpha (TNF-α), NOD-like receptor family pyrin domain containing 3 (NLRP3), Apoptosis-associated speck-like protein containing a CARD (ASC), Toll-like receptor 4 (TLR4), and Cysteine-dependent aspartate-specific protease-1 (Caspase-1) in the brain tissue of rats were detected using RT-qPCR and Western blotting. Immunofluorescence was used to detect NF-κB and TNF-α protein expression.
resultsSTQJD markedly improved neurological function, reduced cerebral infarct volume, and mitigated neuronal damage and apoptosis in rats subjected to Middle Cerebral Artery Occlusion (MCAO). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses revealed that STQJD's anti-IS effects are linked to NOX4/TLR4/NF-κB/TNF-α signaling pathways. STQJD reduced serum levels of inflammatory markers, including TNF-α, Interleukin-1 beta (IL-1β), and Interleukin-18 (IL-18), as well as mRNA and protein expression of TLR4, NOX4, NLRP3, NF-κB, ASC, TNF-α, and Caspase-1 in the brain tissues of MCAO rat levels.
conclusionSTQJD effectively ameliorates IS in MCAO/R rats by modulating the NOX4/TLR4/NF-κB/TNF-α signaling pathway, reducing inflammation and oxidative damage, and exerting neuroprotective effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.